Medication Management for Patent Foramen Ovale
Primary Recommendation
For patients under 60 years old with PFO and cryptogenic stroke after extensive workup excludes other causes, pursue PFO closure followed by antiplatelet therapy rather than antiplatelet or anticoagulation therapy alone 1.
Clinical Decision Algorithm
Step 1: Determine Patient Eligibility and Clinical Context
Age and Stroke Status:
- Age <60 years with cryptogenic ischemic stroke: Primary candidates for intervention 1
- Age >60 years: Benefits less certain; fewer cryptogenic strokes caused by paradoxical emboli, smaller benefits, greater harms expected 1
- No prior stroke: Insufficient evidence for primary prevention; screening not recommended 2
Workup Requirements:
- Extensive evaluation must exclude other stroke etiologies before attributing to PFO 1
- Use PASCAL classification system combining RoPE score with anatomical features (large shunt, atrial septal aneurysm) to categorize PFO as "probable," "possible," or "unlikely" cause 3, 4
Step 2: Treatment Selection Based on Patient Circumstances
Scenario A: All Options Available (Patient Open to All Treatments)
Weak recommendation: PFO closure + antiplatelet therapy over anticoagulation 1
- PFO closure may confer little or no difference in stroke recurrence compared to anticoagulation (low certainty) 5
- However, closure probably has lower risk of major bleeding (20 fewer events per 1000 patients over 5 years) compared to anticoagulation 5
- Anticoagulation probably increases major bleeding risk compared to alternatives 5
Scenario B: Anticoagulation Contraindicated, Declined, or Unavailable
Strong recommendation: PFO closure + antiplatelet therapy over antiplatelet therapy alone 1
- Substantial stroke reduction: 87 fewer recurrent ischemic strokes per 1000 patients over 5 years (moderate certainty) 5
- Pooled analysis of 6 trials (3740 patients): annualized stroke incidence 0.47% with closure vs 1.09% with medical therapy (adjusted HR 0.41,95% CI 0.28-0.60) 3
- PASCAL "probable" patients (younger, no vascular risk factors, high-risk PFO anatomy): 90% relative risk reduction at 2 years (HR 0.10, absolute risk reduction 2.1%) 3
Scenario C: PFO Closure Contraindicated, Declined, or Unavailable
Weak recommendation: Anticoagulation over antiplatelet therapy 1
- Anticoagulation may reduce stroke recurrence (71 fewer per 1000 over 5 years, low certainty) 5
- Major caveat: Probably increases major bleeding (12 additional events per 1000, moderate certainty) 5
- Further research may alter this recommendation 1
Step 3: Risk Stratification for Patient Selection
Use PASCAL Classification to Guide Closure Decisions 3, 4:
PASCAL "Probable" (Best Candidates for Closure):
- Younger patients
- Absent vascular risk factors (no diabetes, hypertension, hyperlipidemia)
- High-risk PFO anatomical features: large right-to-left shunt AND atrial septal aneurysm 3, 4
PASCAL "Unlikely" (Suggest Against Closure):
- Older patients with vascular risk factors
- No high-risk PFO anatomical features
- These patients showed no stroke reduction benefit but higher procedure-related adverse events 3, 4
Important Harms and Considerations
Risks of PFO Closure:
- Persistent atrial fibrillation: 18 additional cases per 1000 patients (moderate certainty) 5
- Device-related adverse events: 36 additional events per 1000 (high certainty) 5
- Procedure takes <2 hours, 1-day hospital stay, full recovery within weeks 1
Post-Closure Management:
- Antiplatelet therapy should follow PFO closure 1
- Suggest against long-term anticoagulation unless indicated for other medical reasons 4
- Duration of antiplatelet therapy may be indefinite or discontinued months after closure 1
- Consider long-term cardiac monitoring for atrial fibrillation, though uncertainty remains regarding risks/benefits of implantable loop recorders 4
Critical Pitfalls to Avoid
Don't close PFO without proper patient selection: PASCAL "unlikely" patients derive no benefit and experience harm 3
Don't assume all PFOs cause stroke: Only 50% of cryptogenic strokes in patients <60 have PFO (vs 25% general population prevalence) 3
Age matters significantly: Applicability to patients >60 is uncertain; traditional vascular risk factors make PFO less likely as stroke etiology 1
Complete workup is mandatory: Must exclude other stroke etiologies before attributing to PFO 1
Don't use anticoagulation routinely: Evidence is weaker than for antiplatelet therapy, with higher bleeding risk 5
Evidence Quality Notes
The 2018 BMJ guideline 1 provides the strongest framework, using GRADE methodology with high-quality evidence for PFO closure vs antiplatelet therapy. The 2025 JAMA review 3 and 2024 ESO guidelines 4 incorporate the PASCAL classification system, representing the most current approach to patient selection. The evidence base shows heterogeneous benefits across trial populations, making proper patient selection using PASCAL classification essential for optimizing outcomes.